search
Back to results

tDCS, Stress and Risk for Schizophrenia (3S)

Primary Purpose

Schizophrenia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Transcranial stimulation in direct current
Sponsored by
Hôpital le Vinatier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Schizophrenia focused on measuring tDCS, non invasive brain stimulation

Eligibility Criteria

18 Years - 30 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject to genetic risk of schizophrenia, related first-degree schizophrenic patient
  • Man and woman
  • Age between 18 and 30 years old

Exclusion Criteria:

  • Contraindications to the practice of the tDCS, for safety measure, we will use the same contraindications as the practice of the Magnetic resonance imaging
  • Psychiatric disorder on axis I of DSM 5
  • Pregnant or nursing women

Sites / Locations

  • Centre Hospitalier Le VinatierRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Transcranial stimulation in direct current(tDCS)active

Transcranial stimulation in direct current(tDCS) placebo

Arm Description

30 minutes of active Transcranial stimulation in direct current

30 minutes of placebo stimulation

Outcomes

Primary Outcome Measures

Cortisol
Salivary cortisol will be analyzed, using Salivette tubes

Secondary Outcome Measures

Decision-making capacities
Decision-making capacities will be measured using a computerized version of the delay discounting task in which participants have to choose between 2 rewards
electroencephalography
EEG will be acquired twice. It consists in an at rest recording of EEG 64 channels, eyes closed to measure spectral power intensities

Full Information

First Posted
July 5, 2017
Last Updated
August 11, 2022
Sponsor
Hôpital le Vinatier
search

1. Study Identification

Unique Protocol Identification Number
NCT03217357
Brief Title
tDCS, Stress and Risk for Schizophrenia
Acronym
3S
Official Title
Effects of Transcranial Direct Current Stimulation on Stress Reactivity and Decision Making in Unaffected Siblings of Patients With Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 2, 2019 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
July 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hôpital le Vinatier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
An exacerbated response to stress mediated by activation of the Hypothalamo-Pituitary-Adrenocortical (HPA) axis is thought to play an important role in the onset, worsening and relapse of schizophrenia. Subjects at risk for schizophrenia (unaffected siblings of patients) displayed an intermediate hyperreactivity to stress as compared with patients and healthy controls. Symptoms of schizophrenia can be reduced with noninvasive brain stimulation (NIBS) applied over the dorsolateral prefrontal cortex (DLPFC). Importantly, this same DLPFC NIBS protocol can modulate decision making processes and modulate biological reactivity to stress by decreasing salivary cortisol concentration in acute stress condition.
Detailed Description
The objective of this project is to evaluate how the modulation of DLPFC activity in acute stress condition influences decision-making in unaffected siblings of patients with schizophrenia. Methods: 30 unaffected siblings of patients with schizophrenia will be enrolled and randomized into 2 groups. 15 subjects will receive active tDCS (2mA, 30 min, anode left DLPFC, cathode right DLPFC) and 15 will receive sham tDCS. tDCS procedure: There is a total of 30 minutes of stimulation at the intensity of 2mA (ramp up and ramp down: 30 sec). Sham stimulation consists in delivering 1 minute of real stimulation. The stimulation site (DLPFC) will be anatomically determined according to 10/20 EEG system (F3 & F4). This procedure is in accordance with international guidelines for safety. Safety and blinding will be assessed using specific tools at the end of the protocol. Stress paradigm: In order to induce moderate stress in humans in laboratory condition, the investigators will use the Maastricht Acute Stress Test (MAST). This test is a combination between physical (hand immersion in cold water) and cognitive (arithmetic calculation) stress. Test will start 5 minutes after the beginning of stimulation session. Decision-making paradigm: The decision-making task will be performed before and after the MAST (during the stimulation) in order to compare changes induce by stress and/or stimulation. The choose test is the Delay Discounting Task (DDT) permitting a measure of decision-making, reward seeking and impulsivity. Stress measure: Saliva samples will be collected using a Salivette®, samples will be stored frozen (- 20°C). Saliva cortisol levels will be measured by ELISA. The investigators also will measure heart rate, systolic and diastolic blood pressures at each time of saliva extraction (each 15 minutes, 1st sample at 9:00 am, please see figure 1). Anxiety will be assessed using the State-Trait Anxiety Inventory (STAI) before and after stimulation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
tDCS, non invasive brain stimulation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
In a randomized controlled double blind study, 30 subjects, first-degree relatives of schizophrenic patients, were randomly assigned to 2 groups. A group of 15 participants will receive 30 minutes of active tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC); A group of 15 participants will receive 30 minutes of placebo stimulation. During this stimulation session, all participants will undergo a standardized stress test combining psychosocial stress and physical stress
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The subject will be blind of the treatment he receives (active or placebo). - The experimenter will also be blinded from stimulation (active or placebo) Each subject will be assigned a randomization code, corresponding to the code to enter the tDCS device. This system allows the person who administers tDCS and the subject receiving the stimulation to be blind .
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transcranial stimulation in direct current(tDCS)active
Arm Type
Active Comparator
Arm Description
30 minutes of active Transcranial stimulation in direct current
Arm Title
Transcranial stimulation in direct current(tDCS) placebo
Arm Type
Placebo Comparator
Arm Description
30 minutes of placebo stimulation
Intervention Type
Device
Intervention Name(s)
Transcranial stimulation in direct current
Intervention Description
tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
Primary Outcome Measure Information:
Title
Cortisol
Description
Salivary cortisol will be analyzed, using Salivette tubes
Time Frame
One year
Secondary Outcome Measure Information:
Title
Decision-making capacities
Description
Decision-making capacities will be measured using a computerized version of the delay discounting task in which participants have to choose between 2 rewards
Time Frame
6 mois
Title
electroencephalography
Description
EEG will be acquired twice. It consists in an at rest recording of EEG 64 channels, eyes closed to measure spectral power intensities
Time Frame
6 mois

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject to genetic risk of schizophrenia, related first-degree schizophrenic patient Man and woman Age between 18 and 30 years old Exclusion Criteria: Contraindications to the practice of the tDCS, for safety measure, we will use the same contraindications as the practice of the Magnetic resonance imaging Psychiatric disorder on axis I of DSM 5 Pregnant or nursing women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
D AMATO THIERRY, MD - PhD
Phone
00334 37 91 51 36
Email
thierry.damato@ch-le-vinatier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
BRUNELIN JEROME, PhD
Phone
00334 37 91 55 65
Email
jerome.brunelin@ch-le-vinatier.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
D AMATO THIERRY, MD - PhD
Organizational Affiliation
CH LE VINATIER
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Le Vinatier
City
Bron Cedex
ZIP/Postal Code
69678
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thierry D'AMATO, PH
Phone
04 37 91 51 00
Email
thierry.damato@ch-le-vinatier.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

tDCS, Stress and Risk for Schizophrenia

We'll reach out to this number within 24 hrs